Development programme

ADJUNCT — liraglutide as adjunct in type 1 diabetes

Two trials of liraglutide added to insulin in type 1 diabetes. The Institute records the programme as a boundary case where a modest glycaemic gain was offset by hypoglycaemia and ketosis.

Sponsor class: Manufacturer-sponsored. First record: 2013.

Filter by text

Phase

Status

Showing 0 records on this page

Records in this programme

10 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
ADJUNCT-ONE	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	1,398	2016	Moderate
ADJUNCT-TWO	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	835	2016	Moderate
ADJUNCT-ONE-BODY-COMPprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
ADJUNCT-ONE-QOLprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
ADJUNCT-ONE-REGIONAL-CNprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
ADJUNCT-ONE-REGIONAL-JPprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
ADJUNCT-TWO-ADHERENCEprogramme record	Liraglutide	Phase 3	Reported	Observational	—	2016	Very low
ADJUNCT-TWO-BIOMARKERprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
ADJUNCT-TWO-ELDERLYprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
ADJUNCT-TWO-OLEprogramme record	Liraglutide	Phase 3	Reported	Single-arm open-label	—	2016	Very low